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ABSTRACT
Women with polycystic ovary syndrome (PCOS) have chronic
anovulation and hyperandrogenism and frequently have abnormal-
ities in their lipid profiles and insulin/insulin-like growth factor axis
that increase their lifetime risk for cardiovascular disease. Normal
ovulatory women may have polycystic ovaries on ultrasonography
and yet lack the clinical features of PCOS. To further explore whether
ovulatory women without clinical/biochemical hyperandrogenism but
with polycystic appearing ovaries (ov-PAO) have subclinical features
of PCOS, we prospectively characterized 26 ov-PAO women and
matched them by age and body mass index to 25 ovulatory women
with normal appearing ovaries (ov-NAO) and to 22 women with
PCOS. After an overnight fast, all women had baseline endocrine and
metabolic assessments. In addition, a subset of each group of women
underwent GnRH-agonist (leuprolide acetate 1 mg sc) testing, ACTH
stimulation, and an insulin tolerance test (ITT). At baseline, ov-PAO
and ov-NAO women had similar endocrine profiles (LH, LH:FSH,
androstenedione, and DHEAS). Compared with ov-NAO, 31% of ov-
PAO women had reduced glucose responses after insulin (Kitt), sug-
gesting mild insulin resistance, and 35% had high density lipoprotein
levels below 35 mg/dL, a level considered to represent significant
cardiovascular risk. After GnRH-agonist, ov-PAO women had re-
sponse patterns in LH, total testosterone, and 17-hydroxyprogester-
one (17-OHP) that were intermediate between ov-NAO and women
with PCOS. Ovarian responses were above the normal range in 30–
40% of women with ov-PAO. In ov-PAO, peak responses of LH after
leuprolide correlated with triglyceride levels (P , 0.05) and peak
responses of 17-OHP correlated inversely with Kitt values (P , 0.05).
No significant differences were noted with ACTH testing. In conclu-
sion, occult biochemical ovarian hyperandrogenism may be uncovered
using GnRH-agonist in ovulatory women with ov-PAO, while adrenal
responses remain normal. Subtle metabolic abnormalities may also be
prevalent. (J Clin Endocrinol Metab 85: 995–1000, 2000)
POLYCYSTIC ovary syndrome (PCOS) is a heteroge-neous clinical disorder characterized primarily by
chronic anovulation and hyperandrogenism (1, 2). It is a
commonly encountered endocrinopathy with a prevalence of
approximately 5–7% of women of reproductive age (3). The
disorder is associated with significantly increased risks of
hypertension, impaired glucose tolerance, and cardiovascu-
lar disease (4–6). Characteristics of PCOS that are thought to
contribute to these disorders are hyperinsulinemia or insulin
resistance, hyperandrogenism, and abnormal lipid/lipopro-
tein profiles (4, 6–8).
Strict criteria for the ultrasonographic diagnosis of the
polycystic ovary have been established and include the pres-
ence of ten or more peripherally oriented cysts in one sono-
graphic plane, each 2–8 mm in diameter, arranged around a
dense stroma. The central stromal mass should occupy at
least 25% of the total volume (9–10). While this sonographic
finding has been used as the sole criterion for the diagnosis
of PCOS, polycystic appearing ovaries (PAO) can be encoun-
tered in several endocrinopathies such as hypothyroidism,
Cushing’s disease, congenital adrenal hyperplasia, and hy-
pothalamic amenorrhea (11), and may occur in 16–25% of
normal women (11–13). While women diagnosed with PCOS
typically have polycystic ovaries, the disorder requires the
presence of chronic anovulation and clinical/biochemical
hyperandrogenism.
Normal ovulatory women with the isolated finding of
polycystic ovaries on ultrasound are not considered to
have PCOS if they are asymptomatic and have normal
serum androgens (ovarian and adrenal), LH, and LH:FSH
ratios. Nevertheless, we have noted that some women
have subtle metabolic abnormalities that occur in PCOS
such as elevated fasting insulin, decreased insulin-like
growth factor binding protein-1 (14), as well as exagger-
ated ovarian responses to injected gonadotropins (15) sim-
ilar to women with PCOS. In these previous studies, the
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sample size was relatively small, and confirmation was
needed to ascertain whether asymptomatic women with
the isolated finding of PAO do in fact exhibit subtle en-
docrinologic and metabolic abnormalities such as insulin
resistance and how frequently this may occur. Because
women with PAO constitute a large segment of the general
population and because cardiovascular disease is the lead-
ing cause of death in women, we considered it important,
from a public health perspective, to determine whether
normal women with PAO may share some of the risks
associated with PCOS.
We performed a prospective study to further explore
whether women with PAO have similar endocrine and
metabolic profiles as found in PCOS. For the first time, we
assessed dynamic pituitary-ovarian responses to GnRH-
agonist as well as adrenal responses to ACTH stimulation.
GnRH-agonist testing was chosen along with ACTH test-
ing because of the well described endocrine changes
known to occur in women with PCOS. Additionally, we
assessed insulin resistance using the insulin tolerance test,
which has been shown to correlate well with the eugly-
cemic/hyperglycemic clamp studies and the frequently
sampled iv glucose tolerance test (16 –17). Finally, we as-
sessed whether the provoked endocrine responses corre-




A total of 73 women were recruited and divided into 3 groups: group
I) 22 women with characteristic hyperandrogenism, chronic anovula-
tion, and polycystic ovaries on ultrasound (PCOS); group II) 26 ovula-
tory women with no characteristics of PCOS but with the isolated ul-
trasound finding of polycystic-appearing ovaries (ov-PAO) defined by
the presence of ten or more peripherally oriented cysts in one sono-
graphic plane, each 2–8 mm in diameter, arranged around a dense
stroma; and group III) 25 ovulatory women with normal-appearing
ovaries (ov-NAO) on ultrasound and no characteristics of PCOS. All
women were matched for age (,35 yr) and had normal body mass index
(BMI , 26 kg/m2). Specifically, this was a group of nonobese women
with PCOS recruited from our infertility/endocrine clinic. Ov-NAO and
ov-PAO women were recruited from our pool of egg donors, and all had
regular menses every 26–34 days, with no signs of hyperandrogenism.
All subjects were screened,and no other endocrine disturbances (thy-
roid, adrenal) or medical illnesses were found. Informed consent was
obtained from all subjects. The study was approved by the Institutional
Review Board of Columbia University, College of Physicians &
Surgeons.
Protocol
All patients were examined by a transvaginal ultrasound during the
early follicular phase. Their weight, height, and waist-to-hip ratio were
recorded. After 3 days of a high carbohydrate diet and followed by an
overnight fast, baseline blood samples were obtained in the morning, at
0800–1000 h, in the midfollicular phase (cycle days 4–9) for FSH, LH,
total testosterone (T), androstenedione (A4), dehydroepiandrosterone
sulfate (DHEAS), insulin-like growth factor-1 (IGF-1), insulin-like
growth factor binding protein-1 (IGFBP-1), insulin, glucose, cholesterol,
triglyceride, high density lipoprotein (HDL) cholesterol, and low density
lipoprotein (LDL) cholesterol measurements. A subset of women from
the 3 groups (10 ov-NAO, 14 ov-PAO, and 6 PCOS) underwent insulin
tolerance testing, GnRH-agonist testing with leuprolide acetate, and
ACTH stimulation. For the insulin tolerance test, 0.1 m/kg of regular
insulin was administered iv, and glucose levels were obtained at 0, 3, 6,
9, 12, and 15 min. At this time, a 50 mL bolus of 50% dextrose was
administered iv to prevent hypoglycemia. The rate constant for plasma
glucose disappearance (Kitt), an accurate marker of insulin resistance,
was then calculated according to the method of Bonora (16). For GnRH-
agonist testing, leuprolide acetate (1 mg) was administered sc, and
serum LH, 17-OH progesterone (17-OHP), and T measurements were
obtained at 0, 1, 2, 4, and 24 h. For the ACTH stimulation test, serum
levels of A4, T, cortisol, and dehydroepiandrosterone (DHEA) were
measured at 0, 30, 60, and 120 min after cosyntropin (0.25 mg) iv
administration.
Assays
Serum A4, 17-OHP, and DHEA were measured by commercial RIA
methods (Diagnostics Systems Laboratories, Inc. (DSL), Webster, TX).
Serum levels of T, sex hormone binding globulin (SHBG), DHEAS,
cortisol, FSH, LH, and insulin were measured by chemiluminescent
enzyme immunoassays (Immulite, Diagnostic Products Corporation,
Los Angeles, CA). IGF-1 and IGFBP-1 were measured by enzyme-linked
immunosorbent assays (DSL). Glucose was quantified by glucose oxi-
dase method. Plasma levels of cholesterol and triglycerides were de-
termined by standardized enzymatic procedures (Roche Molecular Bio-
chemicals, Mannheim, Germany) on a Hitachi 705 automated
spectrophotometer. HDL cholesterol levels were measured after pre-
cipitation of plasma apoB-containing lipoproteins with phosphotungstic
acid (18), and LDL cholesterol levels were calculated by the Friedewald
formula (19). In all assays, intra-assay and interassay coefficients of
variation did not exceed 6% and 13%, respectively.
Statistics
All data are expressed as the mean 6 sem. Statistical analyses were
performed using SPSS, Inc.-PC. Statistical differences between groups
for baseline variables were determined by ANOVA with Tukey post hoc.
Correlations were analyzed using the Pearson product moment corre-
lation. Differences between groups in the temporal course of provoked
responses were analyzed by repeated measures ANOVA, with baseline
hormonal levels entered as a continuous covariate. A P value of less than
0.05 was considered significant. Additionally, 95% confidence intervals
in normal women (ov-NAO) were calculated to assess abnormal re-
sponses in the ov-PAO group.
Results
The three groups did not differ in age, BMI, or waist-to-hip
ratios (Table 1). As expected, significant differences in the
baseline endocrine profile of PCOS were observed when
compared to ov-NAO and ov-PAO groups (Fig. 1). Specifi-
cally, serum LH, LH:FSH, and androgens (T, free testoster-
one index, A4, and DHEAS) were all significantly elevated
in PCOS. The endocrine profiles of ov-PAO women did not
differ as a group compared with those of ov-NAO. Serum
total testosterone in the ov-PAO group (0.50 6 0.04 ng/mL)
was significantly higher than in ov-NAO (0.29 6 0.02 ng/
mL), but all individual values remained in the normal range.
Fasting metabolic profiles (Fig. 2) revealed significantly
elevated fasting insulin (16.2 6 5.3 mIU/mL) and decreased
IGFBP-1 (38.3 6 5.6 ng/mL) only in the PCOS group. In this
nonobese group of subjects, fasting serum cholesterol, tri-
glyceride, and LDL were not different between groups. Al-
though HDL was lower in PCOS, it was not statistically
TABLE 1. Age, BMI, and waist-to-hip ratios for ov-NAO, ov-PAO,
and PCOS groups
Groups n Age (yr) BMI (Kg/m2) Waist-to-hip ratio
ov-NAO 25 30.2 6 0.8 22.1 6 0.4 0.78 6 0.01
ov-PAO 26 28.0 6 0.7 21.5 6 0.3 0.77 6 0.01
PCOS 22 26.6 6 1.7 22.8 6 0.6 0.81 6 0.01
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different. However, compared to none in ov-NAO, 15% of
women with PAO had HDL levels below 35 mg/dL (Fig. 3).
Kitt values in ov-PAO and ov-NAO did not differ signifi-
cantly, but 31% of ov-PAO women had values that were
below the normal range (3.1%/min), suggesting mild insulin
resistance in a subset of ov-PAO women (Fig. 3).
By ANOVA with repeated measures, GnRH-agonist
provoked LH responses were similar in the three groups
(Fig. 4, left panel). However, 15% of ov-PAO women had
increased LH values at 4 and 24 h that were above the
upper 95% confidence interval of ov-NAO (Fig. 4, right
panel). This peak response of LH in ov-PAO correlated
with triglyceride levels (r 5 0.577, P , 0.05). Serum
17-OHP responses to GnRH-agonist were significantly in-
creased in PCOS (P , 0.05), and although an apparent
intermediate response was noted in the ov-PAO group
(Fig. 4, left panel), it failed to reach statistical significance.
At 2 and 4 h, 38% of ov-PAO women had 17-OHP re-
sponses that were above the upper 95% confidence inter-
val of ov-NAO (Fig. 4, right panel). This increased response
was inversely correlated with Kitt (r 5 20.594, P , 0.05)
(Fig. 5). Similarly, the total testosterone response was in-
creased in PCOS (P , 0.05) and intermediate in ov-PAO
(Fig. 4, left panel). At 2 and 4 h, 62% and 46% of ov-PAO
subjects had T values above the upper 95% confidence
interval of ov-NAO (Fig. 4, right panel).
Cortisol, A4, DHEA and T responses to ACTH stimulation
testing were not significantly different between the three
groups (Fig. 6).
Discussion
One of the most characteristic biochemical abnormalities
in PCOS is inappropriate gonadotropin secretion (20–21) and
exaggerated ovarian responses to gonadotropin (22). Previ-
ously, we have found that ovulatory women with the iso-
lated finding of PAO (ov-PAO) displayed a similarly exag-
gerated ovarian sensitivity to human menopausal
gonadotropin (hMG) stimulation in terms of peak estradiol,
number of follicles, and number of oocytes per hMG ampules
(15). In the present study, both ovulatory groups (ov-NAO
and ov-PAO) had similar baseline values of serum gonad-
otropins (LH, LH:FSH ratio) and androgens that were sig-
nificantly lower than those of PCOS.
The GnRH-agonist, leuprolide acetate, stimulated both pi-
tuitary and ovarian secretion in all three groups of women.
Maximal gonadotropin responses occurred within 4 h and
were similar to those reported elsewhere (22). While basal
levels of LH in the ov-PAO group were normal, LH responses
FIG. 1. Baseline endocrine profiles for ov-NAO, ov-PAO, and PCOS
groups. While significant differences were noted in PCOS, ov-PAO did
not differ from ov-NAO in serum LH, LH:FSH, free testosterone
index, androstenedione, and DHEAS. Although serum total testos-
terone in ov-PAO was statistically higher than ov-NAO, all individual
values remained in the normal range.
FIG. 2. Baseline fasting metabolic profiles in ov-NAO, ov-PAO, and
PCOS.
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to GnRH-agonist were exaggerated only in a subset of ov-
PAO women. Because LH pulse characteristics have not been
studied in ov-PAO women, it remains unclear if this exag-
gerated response to GnRH-agonist reflects an underlying
abnormality of 24-h secretion of LH, which is similar to that
of PCOS. Increased ovarian androgen secretion occurred in
response to GnRH-agonist stimulated release of LH and FSH
in all three groups. These provoked responses were signif-
icantly increased in PCOS and, although intermediate in
ov-PAO, these responses failed to reach statistical signifi-
cance when compared with ov-NAO. However, provoked
ovarian androgenic responses were exaggerated in 30–40%
of women with ov-PAO. These increased androgenic re-
sponses are consistent with previous findings of exaggerated
testosterone and androstenedione responses after hMG and
hCG stimulation in two ov-PAO women (14). These findings
may represent an increased ovarian sensitivity to GnRH-
agonist and gonadotropin stimulation in ov-PAO women,
and they suggest an abnormal regulation of their 17-hydrox-
ylase and C-17,20-lyase in the ovarian D4 pathway, which is
similar to that of PCOS (22). Although ov-PAO women are
not hyperandrogenic at baseline testing, GnRH-agonist test-
ing can uncover exaggerated androgenic responses (occult
hyperandrogenism) in a large subgroup of women with
PAO.
Women with PCOS are known to have increased risks
for cardiovascular disease (4 – 6, 23–25). It has been esti-
mated that women with PCOS have a 7-fold relative risk
for myocardial infarction (6). By the time women with
PCOS reach perimenopause, up to 40% will have devel-
oped hypertension, and 16% will have become diabetic (5).
In young women with PCOS, these increased risks are
associated with insulin resistance and abnormal lipid pro-
files (4, 6, 8). We and others have found reduced levels of
IGFBP-I to be another characteristic feature of women with
PCOS (14, 26 –29). This decreased level of IGFBP-1 in turn
may increase the ratio of IGF-I:IGFBP-1 levels and may
possibly lead to increased bioavailable levels of free IGF-I.
High levels of insulin and bioavailable IGF-I may lead to
LH augmentation of androgen biosynthesis and secretion
(30 –31), as well as to pituitary release (31–32). Further-
more, elevated fasting insulin levels have been implicated
in the alterations of ovarian morphology such as polycys-
tic changes (33). Previously, we have found that ov-PAO
women have elevated fasting insulin levels and reduced
levels of IGFBP-1 (14). In the present larger series of lean
FIG. 3. Scattergrams of individual ov-PAO’s HDL levels (normal . 35
mg/dL) and Kitt values (normal . 3.1%/min.) compared with those of
ov-NAO.
FIG. 4. GnRH-agonist provoked responses of LH, 17-OHP, and T (left
panel) analyzed by repeated measures ANOVA, with baseline hor-
monal levels entered as continuous covariate. Scattergrams of pro-
voked LH, 17-OHP, and T responses in ov-PAO and the proportions
(shown in parentheses) that were over the 95% confidence interval in
ov-NAO (right panel).
998 CHANG ET AL. JCE & M • 2000
Vol 85 • No 3
women with PAO, we failed to confirm our previous find-
ings regarding alterations of the insulin-IGF axis, but we
found that up to one third have subtle metabolic abnor-
malities. While the average levels in ov-PAO did not differ
as a group when compared with ov-NAO, 15% of women
with ov-PAO had HDL levels below 35 mg/dL, a level
considered to constitute significant cardiovascular risk
(34). In fact, the average HDL level for white females is 55
mg/dL (35), and a level below 35 mg/dL corresponds to
the lowest 5th percentile for the general female population
(36). In addition, 31% of ov-PAO had Kitt levels below
normal. Moreover, Kitt levels were inversely correlated
with increased 17-OHP response to GnRH-agonist in the
ov-PAO group, suggesting a greater androgenic response
with insulin resistance. The women with PCOS in this
study were not obese and were matched by BMI and age
to the ovulatory groups. It may be for this reason that the
overall prevalence of metabolic abnormalities was not
high.
When the adrenals were stimulated with a pharmacologic
dose of ACTH, no significant differences were noted in the
response pattern between the three groups of women. Previous
investigators have used pharmacologic, physiologic, or endog-
enous ACTH for disclosing subclinical abnormalities in adrenal
steroidogenesis in some women with PCOS (37–41), while oth-
ers have failed to note such significant changes (42–43). Al-
though women with PCOS in this study had elevated adrenal
androgens (DHEAS) at baseline, they did not exhibit significant
adrenal hyperandrogenic responses to ACTH when compared
with ov-PAO and control groups. Because ov-PAO subjects in
this study had normal adrenal responses to ACTH, but some
abnormal ovarian responses to GnRH-agonist, it suggests that
this resemblance to PCOS may be linked to this altered ovarian
morphology, which may present with subtle ovarian but not
adrenal hyperandrogenism.
While it is not entirely clear if asymptomatic women
with this isolated ultrasound finding exhibit all of the
endocrine abnormalities and cardiovascular risk factors of
PCOS, the present data confirm and extend our previous
findings in that up to one third of women with PAO may
have subtle findings consistent with PCOS. Because these
responses were provoked, some women with PAO may
merely carry a risk for the full development of PCOS.
Nevertheless, because many of these subjects had meta-
bolic abnormalities linked to cardiovascular disease, and
because cardiovascular disease is the leading cause of
death in women, our findings suggest that monitoring all
women with polycystic ovaries for these risks may be
important in the health care of women.
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FIG. 5. Ov-PAO peak 17-OHP responses to leuprolide correlate in-
versely with Kitt, suggesting greater hyperandrogenic responses with
mild insulin resistance.
FIG. 6. Adrenal responses of cortisol, A4, T, and DHEA to ACTH
stimulation were not significantly different among the three groups
by repeated measures ANOVA with baseline hormonal levels entered
as continuous covariate.
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